Insulin Management

Jennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, discusses how pharmacists can collaborate with providers to optimize insulin therapy.

Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, discusses how pharmacists can help patients manage insulin.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses how diabetes advancements like GLP-1s and CGM have impacted the management of insulin.

Researchers conducted a narrative review of the insulins available for diabetes management and which pharmacological options are best in the perioperative period and within clinical care.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joins Drug Topics to discuss her extensive background in managing patients’ insulin regimens.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the importance of insulin delivery and the common barriers pharmacists face in managing patients’ regimens.

Researchers explored the effectiveness of telephonic insulin titration by a clinical pharmacist compared with in-office titration among patients in a medical residency clinic.

Efsitora demonstrates noninferior reductions in hemoglobin A1c and similar rates in patients with an A1c level less than 7% compared with common daily insulin.

Patients who used the Bigfoot Unity Diabetes Management System had glycemic control and reduced diabetes distress.

Control-IQ+ was associated with a greater reduction in glycated hemoglobin compared to a continuous glucose monitor alone.

These findings challenge the common assumption that older adults might struggle to use more advance medical devices.

Children with type 1 diabetes who watched educational videos and played games had improved glycemic control and quality of life.

MannKind announced results from the INHALE-1 study that examined Afrezza in children and adolescents with diabetes.

Medication alerts, nurse education, and pharmacist interventions led to lower hypoglycemic events every year after they were implemented.

Two phase 3 trials demonstrated that once-weekly insulin efsitora is as effective as daily insulin in lowering HbA1c in both type 1 (T1D) and type 2 diabetes (T2D).